Viral infectious illnesses represent a severe hazard to human health due to their widespread
incidence worldwide. Among these ailments, the dengue virus (DENV) infection stands
out. World Health Organization (WHO) estimates that DENV infection affects ~400 million
people each year, with potentially fatal symptoms showing up in 1% of the cases. In several instances,
academic and pharmaceutical researchers have conducted several pilot and clinical studies
on a variety of topics, including viral epidemiology, structure and function analyses, infection
source and route, therapeutic targets, vaccinations, and therapeutic drugs. Amongst Takeda,
TAK-003, Sanofi, Dengvaxia®, and Butantan/NIH/Merck, Dengvaxia® (CYD-TDV) is the only
licensed vaccination yet; however, the potential inhibitors are under development. The biology
and evolution of DENVs are briefly discussed in this review, which also compiles the most recent
studies on prospective antiviral targets and antiviral candidates. In conclusion, the triumphs
and failures have influenced the development of anti-DENV medications, and the findings in this
review article will stimulate more investigation.